Hypertension, Kidney and Pregnancy

高血压、肾脏和怀孕

• 批准号: 8433334
• 负责人: Joey P. Granger
• 金额: $ 35.58万
• 依托单位: UNIVERSITY OF MISSISSIPPI MED CTR
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-04-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8433334
• 关键词: Affect; Angiogenic Factor; Attenuated; Autoantibodies; Bilirubin; Birth; Blood Pressure; Carbon Monoxide; Cardiovascular Diseases; Cell Culture Techniques; Cessation of life; Chronic; Conscious; Coronary Arteriosclerosis; Cytoprotection; Data; Disease; End stage renal failure; Endothelial Cells; Endothelin; Endothelin-1; Enzymes; Event; Excretory function; Functional disorder; Genes; Glomerular Filtration Rate; Health; Heart failure; Hypertension; Hypertension induced by pregnancy; Hypoxia; In Vitro; Inflammatory; Investigation; Ischemia; Kidney; Mediating; Modeling; Morbidity - disease rate; Oxygen; Pathway interactions; Perfusion; Perinatal; Peripheral Resistance; Pharmaceutical Preparations; Placenta; Placental Growth Factor; Plasma; Play; Positioning Attribute; Pre-Eclampsia; Pregnancy; Production; Publishing; Rattus; Reactive Oxygen Species; Renal Plasma Flow; Renal function; Risk Factors; Role; Series; Stroke; TNF gene; Testing; Tissues; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factors; Villous; Woman; base; biological adaptation to stress; cell injury; cytokine; effective therapy; heme oxygenase-1; improved; in vitro Model; instrument; new therapeutic target; novel therapeutic intervention; peripheral blood; pregnant; pressure; prevent; receptor; response; vascular endothelial dysfunction

DESCRIPTION (provided by applicant): Pregnancy-induced hypertension or preeclampsia (PE) is estimated to affect 5-7% of all pregnancies in the U.S. Despite its position as a leading cause of maternal death and major contributor to maternal and perinatal morbidity, there is no effective drug treatment to prevent PE. At present, the only effective treatment for PE is early delivery. Based on recent studies and on preliminary data presented in this application, we propose that induction of the stress response gene, hemeoxygenase-1 (HO-1), and its catalytic products, carbon monoxide (CO) and bilirubin, may provide a novel therapeutic approach for the treatment of PE. There is mounting evidence that HO-1 and/or its catalytic products confer cytoprotection against cellular injury in response to placental ischemia, an important initiating event in the pathophysiology of PE. In fact, TNF1 mediated cellular damage in placental villous explants can be prevented by up-regulating HO activity. HO pathways have also been shown to inhibit the release of the anti-angiogenic factor, sFlt-1, in several in vitro models. Our preliminary data also indicates that chronic administration of an HO-1 enzyme inducer or a CO releasing molecule significantly attenuates hypertension in two well-established rat models of PE. Based on our preliminary data, we propose to test the central hypothesis that HO-1 and its metabolites, CO and bilirubin, attenuate the blood pressure and renal responses to placental ischemia in pregnant rats by inhibition of sFlt-l production. In addition, we propose that HO-1 derived products improve renal function and decrease total peripheral resistance and blood pressure by inhibiting the placental production of TNF1 and reactive oxygen species (ROS) and attenuating TNF1 and AT1 receptor autoantibody -induced increases in endothelial cell production of endothelin (ET-1). To test this hypothesis, arterial pressure, renal function, and endothelial factors will be examined in a conscious rat model of PE produced by long-term reductions in uterine perfusion pressure (RUPP). In addition to the RUPP model, a sFlt-1 model of PE will be used to determine the interaction between the HO-1 metabolites and sFlt-1, ET-1, and ROS production while in vitro placental explant and endothelial cell culture models will be used to examine the direct interaction of HO-metabolites in hypoxia- mediated induction of TNF, ROS and placental sFlt-1 and TNF induced ET-1 production. Specific aims are: 1) To test the hypothesis that HO-1 and its metabolites, CO and bilirubin, attenuate the blood pressure, renal, and sFlt-1 responses to placental ischemia in pregnant rats 2) To test the hypothesis that HO-1 and its metabolites, CO and bilirubin, attenuate placental ischemia and/or hypoxia-induced increases in reactive oxygen species and TNF1 3) To test the hypothesis that HO-1 and its metabolites, CO and bilirubin, attenuate TNF1 and AT1 receptor autoantibody- induced increases in ET-1 production 4) To test the hypothesis that the endogenous HO-1 pathway plays a role in regulating renal function and arterial pressure during normal pregnancy and in response to placental ischemia

描述（由申请人提供）：据估计，妊娠高血压或先兆子痫（PE）影响美国所有妊娠的5-7%。尽管它是孕产妇死亡的主要原因，也是孕产妇和围产期发病率的主要贡献者，但没有有效的药物治疗来预防PE。目前，PE的唯一有效治疗方法是早期分娩。基于最近的研究和本申请中提出的初步数据，我们提出诱导应激反应基因血红素加氧酶-1（HO-1）及其催化产物一氧化碳（CO）和胆红素，可能为治疗PE提供一种新的治疗方法。越来越多的证据表明，HO-1和/或其催化产物赋予细胞保护作用，以对抗胎盘缺血引起的细胞损伤，这是PE病理生理学中的重要起始事件。事实上，TNF 1介导的胎盘绒毛外植体细胞损伤可以通过上调HO活性来预防。在几种体外模型中，HO途径也显示出抑制抗血管生成因子sFlt-1的释放。我们的初步数据还表明，长期给予HO-1酶诱导剂或CO释放分子可显着减轻两种已建立的PE大鼠模型中的高血压。基于我们的初步数据，我们建议测试中心的假设，HO-1及其代谢产物，CO和胆红素，减弱血压和肾脏的反应，胎盘缺血在妊娠大鼠通过抑制sFlt-1生产。此外，我们提出HO-1衍生产物通过抑制TNF-1和活性氧（ROS）的胎盘产生以及减弱TNF-1和AT-1受体自身抗体诱导的内皮细胞产生内皮素（ET-1）的增加来改善肾功能并降低总外周阻力和血压。为了检验这一假设，将在通过长期降低子宫灌注压（RUPP）产生的清醒大鼠PE模型中检查动脉压、肾功能和内皮因子。除了RUPP模型之外，PE的sFlt-1模型将用于确定HO-1代谢物与sFlt-1、ET-1和ROS产生之间的相互作用，而体外胎盘外植体和内皮细胞培养模型将用于检查HO-代谢物在缺氧介导的TNF、ROS诱导和胎盘sFlt-1和TNF诱导的ET-1产生中的直接相互作用。具体目标是：1）检验HO-1及其代谢产物CO和胆红素减弱妊娠大鼠对胎盘缺血的血压、肾脏和sFlt-1反应的假设2）检验HO-1及其代谢产物CO和胆红素，减弱胎盘缺血和/或缺氧诱导的活性氧和TNF 1的增加3）为了检验HO-1及其代谢物，CO和胆红素，减弱TNF-1和AT-1受体自身抗体诱导的ET-1产生增加4）验证内源性HO-1通路在正常妊娠期间和胎盘缺血反应中调节肾功能和动脉压的作用的假设